Back to Search
Start Over
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.
- Source :
-
Arthritis care & research [Arthritis Care Res (Hoboken)] 2019 Jun; Vol. 71 (6), pp. 703-716. Date of Electronic Publication: 2019 Apr 25. - Publication Year :
- 2019
-
Abstract
- Objective: To develop recommendations for the screening, monitoring, and treatment of uveitis in children with juvenile idiopathic arthritis (JIA).<br />Methods: Pediatric rheumatologists, ophthalmologists with expertise in uveitis, patient representatives, and methodologists generated key clinical questions to be addressed by this guideline. This was followed by a systematic literature review and rating of the available evidence according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology. A group consensus process was used to compose the final recommendations and grade their strength as conditional or strong.<br />Results: Due to a lack of literature with good quality of evidence, recommendations were formulated on the basis of available evidence and a consensus expert opinion. Regular ophthalmic screening of children with JIA is recommended because of the risk of uveitis, and the frequency of screening should be based on individual risk factors. Regular ophthalmic monitoring of children with uveitis is recommended, and intervals should be based on ocular examination findings and treatment regimen. Ophthalmic monitoring recommendations were strong primarily because of concerns of vision-threatening complications of uveitis with infrequent monitoring. Topical glucocorticoids should be used as initial treatment to achieve control of inflammation. Methotrexate and the monoclonal antibody tumor necrosis factor inhibitors adalimumab and infliximab are recommended when systemic treatment is needed for the management of uveitis. The timely addition of nonbiologic and biologic drugs is recommended to maintain uveitis control in children who are at continued risk of vision loss.<br />Conclusion: This guideline provides direction for clinicians and patients/parents making decisions on the screening, monitoring, and management of children with JIA and uveitis, using GRADE methodology and informed by a consensus process with input from rheumatology and ophthalmology experts, current literature, and patient/parent preferences and values.<br /> (© 2019, American College of Rheumatology.)
- Subjects :
- Arthritis, Juvenile epidemiology
Biological Products adverse effects
Consensus
Glucocorticoids adverse effects
Humans
Immunosuppressive Agents adverse effects
Predictive Value of Tests
Risk Factors
Treatment Outcome
Tumor Necrosis Factor Inhibitors adverse effects
Uveitis epidemiology
Arthritis, Juvenile diagnosis
Arthritis, Juvenile drug therapy
Biological Products therapeutic use
Glucocorticoids therapeutic use
Immunosuppressive Agents therapeutic use
Ophthalmology standards
Rheumatology standards
Tumor Necrosis Factor Inhibitors therapeutic use
Uveitis diagnosis
Uveitis drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 2151-4658
- Volume :
- 71
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Arthritis care & research
- Publication Type :
- Academic Journal
- Accession number :
- 31021540
- Full Text :
- https://doi.org/10.1002/acr.23871